4DMedical (ASX:4DX): Growth Story Gains Airflow in the US Market

Highlights

• 4DMedical (ASX:4DX) is expanding US traction for CT:VQ after FDA clearance, adding major hospital partners and broadening its commercial footprint.

• A pay-per-scan SaaS model can scale efficiently if scan volumes rise, but adoption speed and operational execution remain the swing factors.

• Deal momentum improves revenue visibility, while investors still weigh cash burn, rollout risk, and valuation expectations.

4DMedical’s CT:VQ rollout is gathering pace in the US via Philips distribution and new hospital partners. The focus now shifts to scan volumes, execution, and cash burn control.

4DMedical (ASX:4DX) is increasingly being framed as an ASX medtech with a credible US scale-up pathway, as CT:VQ adoption starts to move from early validation into broader deployment. The narrative is being driven by a growing list of institutional relationships and a distribution push that aims to make CT:VQ easier for US hospitals to adopt without building bespoke commercial pipelines site-by-site.

What is CT:VQ and why is the US market the prize?

Entity-rich definition: CT:VQ
CT:VQ is a lung imaging software approach designed to quantify ventilation and perfusion from CT-based workflows, supporting clinical assessment of airflow and blood flow patterns in the lungs.

The US represents the largest near-term commercial opportunity because it is a high-volume imaging market with established reimbursement pathways across many categories, plus a dense network of large academic and hospital systems that can accelerate clinical adoption once a technology becomes “standard practice” inside major institutions.

Why the recent partnerships matter

1) Institutional adoption acts like a credibility flywheel

When major hospitals or universities adopt a new imaging workflow, it can trigger second-order effects:

• peer institutions benchmark results and consider adoption

• clinicians generate more data and clinical familiarity

• internal champions emerge and drive usage growth over time

Each additional credible site can make subsequent adoption easier—particularly in clinical software, where trust, workflow integration, and evidence matter as much as the product itself.

2) A distribution partner can shorten sales cycles

A large distribution relationship can reduce friction for hospitals already buying adjacent imaging solutions. For investors, the key benefit is not just headline contract value, but the potential to compress time-to-scale by plugging CT:VQ into existing procurement and commercial channels.

The business model: why investors focus on scan volumes

Entity-rich definition: pay-per-scan SaaS
A pay-per-scan software-as-a-service model charges customers based on usage (scan volume), rather than primarily on upfront licence fees, which can create recurring revenue that grows as adoption expands.

This model can offer strong operating leverage if:

• the software deploys efficiently across more sites

• scan volumes per site rise over time

• servicing costs grow slower than revenue

In plain terms, the model gets more attractive the more hospitals move from “trial use” into routine clinical workflow.

What the quarterly operating metrics are signalling

The underlying story investors track is not only “how many sites exist,” but whether those sites are producing rising scan throughput. Higher scan counts suggest that CT:VQ is becoming embedded in repeatable clinical pathways rather than being used only for evaluation or niche cases.

This is where the US rollout becomes pivotal: strong distribution plus expanding clinical partners can convert a growing installed base into sustained scan utilisation.

The key debate: momentum versus execution risk

Even with improving commercial traction, investors typically keep three risks front and centre:

1) Execution and rollout complexity

Scaling medtech software across hospitals involves integrations, training, workflow change, and clinical buy-in. Commercial wins are important, but consistent deployment outcomes are what turn wins into durable utilisation.

2) Cash burn versus runway discipline

A growth-phase medtech can look compelling on gross margin and operating leverage, but markets still punish uncontained burn if revenue growth doesn’t keep pace. Investors usually want to see:

• improving unit economics as volume scales

• steady conversion from “site signed” to “site active”

• a credible pathway to cash flow breakeven

3) Valuation expectations

After strong share-price moves, the market often “pulls forward” part of the future success case. That can make the stock more sensitive to any slowdown in adoption, delays in hospital onboarding, or weaker-than-expected scan utilisation.

What this could mean for 4DMedical (ASX:4DX) from here

The near-term narrative is straightforward: the more CT:VQ becomes routine inside large US networks, the more predictable recurring revenue can become. The next phase of scrutiny usually shifts from announcements to measurable operating proof points—active sites, scan throughput, retention, and the pace at which deployments expand beyond flagship institutions.

For shareholders, the setup looks strongest when:

• commercial partnerships translate into consistent scan growth

• operating leverage shows up in improving margins over time

• dilution risk stays contained through disciplined cash management